Immune checkpoint inhibitors in patients with pretreated HodgkinÊs lymphoma: a Korean single-center, retrospective study

BACKGROUND: Immune checkpoint inhibitors have demonstrated efficacy in the treatment of classical Hodgkin’s lymphoma (cHL). We analyzed the efficacy and safety of pembrolizumab or nivolumab in patients with pretreated cHL. METHODS: Clinical data from the cancer chemotherapy registry of Samsung Medic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hur, Joon Young, Yoon, Sang Eun, Kim, Seok Jin, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343550/
https://www.ncbi.nlm.nih.gov/pubmed/32595170
http://dx.doi.org/10.5045/br.2020.2020014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343550/
https://www.ncbi.nlm.nih.gov/pubmed/32595170
http://dx.doi.org/10.5045/br.2020.2020014

Ejemplares similares